Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization

Cancer Genetics and Cytogenetics

Volumn 123, Issue 2, 2000, Pages 102-108

  Cohen, Ninette ^a   Novikov, Ilya ^a   Hardan, Izhar ^a   Esa, Arif ^b   Brok Simoni, Frida ^a   Amariglio, Ninette ^a   Rechavi, Gideon ^a   Ben Bassat, Isaac ^a   Trakhtenbrot, Luba ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE TRANSLOCATION; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; LABORATORY DIAGNOSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; TECHNIQUE;

CELL NUCLEUS; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; LEUKEMIA, MYELOID, CHRONIC; REFERENCE STANDARDS;

EID: 0034541541     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(00)00315-0     Document Type: Article

References (26)

1. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization
2. Identification of masked and variant Ph (complex type) translocations in CML and classic Ph in AML and ALL by fluorescence in situ hybridization with the use of bcr/abl cosmid probes
3. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL
4. Building a new clinical test for fluorescence in situ hybridization
5. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment
6. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy
7. Some observations on fluorescence in situ hybridization evaluation of chronic myelocytic leukemia
8. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-α therapy
9. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells
10. Cytogenetic and molecular genetic methods for diagnosis and treatment response in chronic granulocytic leukemia
11. Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim)
12. Fast-FISH detection and semi-automated image analysis of numerical chromosome aberrations in hematological malignancies
13. Two-sided confidence intervals for the single proportion; comparison of seven methods
14. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization
15. In vitro proliferative advantage of bone marrow cells with tetrasomy 8 in Ewing sarcoma
16. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization
17. Comparative study of three-dimensional localization accuracy in conventional, confocal laser scanning and axial tomographic fluorescence light microscopy
18. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
19. Improved sensitivity of BCR-ABL detection; a triple probe three-color fluorescence in situ hybridization system
20. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic meyloid leukemia
21. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia
22. Deletions of 9q proximal to ABL accompany variant and standard Philadelphia translocations
23. Fifteen percent of CML patients with Ph translocation characterized by deletions of 9q proximal to the ABL gene; a sub-group?